Tango Therapeutics (TNGX) Price & Analysis

Compare

418 Followers

TNGX Stock Chart & Stats

$9.63

-$0.22(-6.34%)

At close: Jan 08 4:00 PM EST

$9.63

-$0.22(-6.34%)

Day’s Range― - ―

52-Week Range$1.03 - $11.20

Previous CloseN/A

Volume187.94K

Average Volume (3M)3.07M

Market Cap

$1.30B

Enterprise Value$813.64M

Total Cash (Recent Filing)$152.81M

Total Debt (Recent Filing)$34.76M

Price to Earnings (P/E)―

Beta1.43

Next Earnings

Mar 30, 2026

EPS Estimate

-0.32

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.14

Shares Outstanding134,677,100

10 Day Avg. Volume2,676,763

30 Day Avg. Volume3,068,211

Financial Highlights & Ratios

PEG Ratio-0.25

Price to Book (P/B)1.69

Price to Sales (P/S)8.02

P/FCF Ratio-2.55

Enterprise Value/Market Cap0.63

Enterprise Value/Revenue12.24

Enterprise Value/Gross Profit12.46

Enterprise Value/Ebitda-7.83

Forecast

1Y Price Target

$13.67

Price Target Upside41.95% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

EPS Forecast (FY)-0.87

Revenue Forecast (FY)$62.95M

Bulls Say, Bears Say

Bulls Say

Clinical Trials ProgressA pivotal Phase 3 trial for vopimetostat vs. chemo in 2L MTAP-deleted PDAC patients is set to be initiated, indicating progress in clinical trials.

Financial StrengthTango ended 3Q25 with $364.8M in pro forma cash, cash equivalents, and marketable securities, providing an operational runway into 2028.

Treatment EfficacyThe updated data from the ongoing study of vopimetostat showed an overall objective response rate of 27% and a disease control rate of 78%, indicating promising efficacy across various solid tumor indications.

Bears Say

Clinical Results RisksRisks include negative clinical results with the lead asset, TNG462, and delays in advancing pipeline candidates into registrational trials.

Regulatory Approval RisksThere is a risk of failure to achieve favorable clinical results with other candidates, specifically TNG456, and the inability to obtain regulatory approvals in a timely manner.

Tango Therapeutics News

Tango Therapeutics initiated with a Buy at Stifel

Stifel initiated coverage of Tango Therapeutics (TNGX) with a Buy rating and $15 price target The firm views...

4d ago

TNGX

Tango Therapeutics files to sell 1.73M shares of common stock for holders

08:35 EST Tango Therapeutics (TNGX) files to sell 1.73M shares of common stock for holders Published first on...

16d ago

TNGX

Tango Therapeutics files automatic mixed securities shelf

08:35 EST Tango Therapeutics (TNGX) files automatic mixed securities shelf Published first on TheFly – the ultimate source...

16d ago

TNGX

Perspective Therapeutics price target lowered to $11 from $12 at B. Riley

B. Riley lowered the firm’s price target on Perspective Therapeutics (CATX) to $11 from $12 and keeps a...

19d ago

CATX

TNGX

Tango Therapeutics price target raised to $14 from $8 at B. Riley

B. Riley raised the firm’s price target on Tango Therapeutics (TNGX) to $14 from $8 and keeps a...

19d ago

TNGX

Tango Therapeutics initiated with a Peer Perform at Wolfe Research

Wolfe Research initiated coverage of Tango Therapeutics (TNGX) with a Peer Perform rating and no price target Vopimetostat’s...

20d ago

TNGX

Strategic Positioning and Synergy Potential Drive Buy Rating for Tango Therapeutics’ Vopimetostat

Tango Therapeutics (TNGX) has received a new Buy rating, initiated by Stifel Nicolaus analyst, Laura Prendergast. Laura Prendergast’s...

4d ago

TNGX

Tango Therapeutics Enters New Sales Agreement with Leerink

Tango Therapeutics ( ($TNGX) ) has provided an update. On November 21, 2025, Tango Therapeutics entered into a...

16d ago

TNGX

Tango Therapeutics Reports Promising Q3 2025 Results

Tango Therapeutics, Inc. ( ($TNGX) ) has released its Q3 earnings. Here is a breakdown of the information...

1M ago

TNGX

Tango Therapeutics reports Q3 EPS 14c, consensus (7c)

Reports Q3 revenue $53.811M, consensus $41.24M. “We are wrapping up 2025 with significant momentum, supported by our recent...

1M ago

TNGX

Tango Therapeutics, Inc. (TNGX) Q3 Earnings Cheat Sheet

Tango Therapeutics, Inc. (TNGX) is scheduled to report 3rd quarter earnings on 11/04/2025, before the market opens. Regarding...

1M ago

TNGX

Tango Therapeutics Advances Innovative Cancer Treatment with S095035 Clinical Trial

Tango Therapeutics, Inc. (($TNGX)) announced an update on their ongoing clinical study. Study Overview: Tango Therapeutics, Inc. is...

1M ago

TNGX

Revolution Medicines and Tango Therapeutics Advance in Targeted Cancer Therapy Study

Revolution Medicines, Inc. (($RVMD)), Tango Therapeutics, Inc. (($TNGX)) announced an update on their ongoing clinical study. Revolution Medicines,...

1M ago

RVMD

TNGX

Tango Therapeutics’ Promising Update on TNG260 Clinical Study

Tango Therapeutics, Inc. (($TNGX)) announced an update on their ongoing clinical study. Tango Therapeutics, Inc. is conducting a...

1M ago

TNGX

TNGX FAQ

What was Tango Therapeutics’s price range in the past 12 months?

Tango Therapeutics lowest stock price was $1.03 and its highest was $11.20 in the past 12 months.

What is Tango Therapeutics’s market cap?

Tango Therapeutics’s market cap is $1.30B.

When is Tango Therapeutics’s upcoming earnings report date?

Tango Therapeutics’s upcoming earnings report date is Mar 30, 2026 which is in 113 days.

How were Tango Therapeutics’s earnings last quarter?

Tango Therapeutics released its earnings results on Nov 04, 2025. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of -$0.051 by $0.191.

Is Tango Therapeutics overvalued?

According to Wall Street analysts Tango Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Tango Therapeutics pay dividends?

Tango Therapeutics does not currently pay dividends.

What is Tango Therapeutics’s EPS estimate?

Tango Therapeutics’s EPS estimate is -0.32.

How many shares outstanding does Tango Therapeutics have?

Tango Therapeutics has 134,677,100 shares outstanding.

What happened to Tango Therapeutics’s price movement after its last earnings report?

Tango Therapeutics reported an EPS of $0.14 in its last earnings report, beating expectations of -$0.051. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Tango Therapeutics?

Currently, no hedge funds are holding shares in TNGX

Tango Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-51.65%

Trailing 12-Months

Asset Growth

-40.37%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Tango Therapeutics

Tango Therapeutics (TNGX) is a biotechnology company focused on developing innovative therapies for the treatment of cancer. The company specializes in precision medicine, leveraging its proprietary technology platform to discover and develop novel therapeutics that target specific genetic vulnerabilities in tumors. Tango Therapeutics operates primarily in the healthcare and pharmaceutical sectors, with a core focus on drug discovery and development aimed at improving patient outcomes in oncology.

Tango Therapeutics (TNGX) Earnings & Revenues

Historic Earnings Reports

TNGX Stock 12 Month Forecast

Average Price Target

$13.67

▲(41.95% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","4":"$4","8":"$8","12":"$12","16":"$16"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$15.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$13.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4,8,12,16],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.42,10.772307692307692,11.124615384615385,11.476923076923077,11.829230769230769,12.181538461538462,12.533846153846154,12.886153846153846,13.23846153846154,13.590769230769231,13.943076923076923,14.295384615384616,14.647692307692308,{"y":15,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.42,10.67,10.92,11.17,11.42,11.67,11.92,12.17,12.42,12.67,12.92,13.17,13.42,{"y":13.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.42,10.541538461538462,10.663076923076924,10.784615384615385,10.906153846153845,11.027692307692307,11.149230769230769,11.27076923076923,11.392307692307693,11.513846153846155,11.635384615384616,11.756923076923076,11.878461538461538,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.15,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.09,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.98,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.07,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.28,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.54,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.44,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.53,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.66,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.98,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.11,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.42,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >